Grifols, S.A. (NASDAQ:GRFS) Position Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 144.0% during the 3rd quarter, Holdings Channel reports. The fund owned 2,002,511 shares of the biotechnology company’s stock after purchasing an additional 1,181,959 shares during the period. JPMorgan Chase & Co.’s holdings in Grifols were worth $17,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in GRFS. Whitebox Advisors LLC increased its holdings in shares of Grifols by 56.2% during the third quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock valued at $37,487,000 after purchasing an additional 1,519,093 shares during the period. Brandes Investment Partners LP increased its stake in Grifols by 8.7% during the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock valued at $117,242,000 after buying an additional 1,481,924 shares during the period. Armistice Capital LLC increased its stake in Grifols by 18.7% during the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after buying an additional 1,244,000 shares during the period. Highland Peak Capital LLC bought a new stake in shares of Grifols during the 2nd quarter worth about $5,991,000. Finally, Black Creek Investment Management Inc. lifted its stake in shares of Grifols by 7.7% in the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after acquiring an additional 881,155 shares during the period.

Grifols Stock Performance

GRFS opened at $7.60 on Friday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The stock’s fifty day moving average is $8.08 and its 200-day moving average is $8.16. Grifols, S.A. has a one year low of $5.30 and a one year high of $9.96.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.